Research

KEBNI: Massive order intake for Saab lowers risk in IMU ramp-up markedly

Analys, Research

In the first half of December, KebNi’s single most important customer, defence company Saab has received two orders for its handheld...

Read More

HILBERT GROUP: Slow & steady wins the race amidst crypto turmoil

Analys, Research

HILBERT GROUP Despite a challenging crypto landscape, with the FTX collapse creating ripple effects throughout the crypto ecosystem,...

Read More

QLUCORE: Structural growth story on track with a slight expansion of long-term scope

Analys, Research

After the strong growth in Q1’22/23, sales bounced back in Q2’22/23, right in line with our forecast. With the process to CE marking of...

Read More

MOTION DISPLAY: Bright spots shining through persistent headwind

Analys, Research

The hangover from the pandemic continues to linger for Motion Display. But there are bright spots. With a well-documented effect on sales,...

Read More

KEBNI: New targets reflect high conviction in strong growth across the board in 2023-2027

Analys, Research

The announcement of KebNi’s revised strategy and financial targets for 2023-2027 reflect a firm conviction in steady long term growth...

Read More

MELTRON: Focus set on positive cash flow

Analys, Research

After a cash injection of SEK 11.3m from the completed rights issue, Meltron now has its sights set on positive cash flow through sales...

Read More

KEBNI: On track to scale up in 2023

Analys, Research

KebNi’s Q3-report provided some further insight into the progress made in setting up volume series production within Inertial Sensing,...

Read More

SIMRIS ALG: Ready to execute on a three-pronged roadmap to capture the most high-value opportunities

Analys, Research

Following the successful acquisition of Cyano Biotech GmbH in Q3, Simris is now moving forward with a three-pronged approach to value...

Read More

DLABORATORY: Strong growth and positive EBITDA a welcome shift in pace

Analys, Research

With a steep increase in revenue, 35% recurring revenue growth, turn to positive EBITDA of SEK 2.2m and a forward-leaning statement from...

Read More

NANEXA: Charging to enter triple clinical trials in the coming year

Analys, Research

Besides starting its third proprietary development project in Q2 (NEX-22, a long-acting formulation of liraglutide for treatment of type 2...

Read More

For new research on growth stocks, sign up to our newsletter